The board of directors of Sino Biopharmaceutical Limited announced that the "Gadoteridol Injection" (trade name: Daxian), a medical imaging product developed by the Group, has received the approval for marketing from the National Medical Products Administration of China. Gadoteridol is a non-ionic magnetic resonance imaging (MRI) contrast agent for the examination of magnetic resonance (MR) enhancement scans applicable to the brain, spine and peripheral tissues lesions, as well as whole-body MRI examinations including examination for the head, neck, liver, mammary glands, musculoskeletal system, and soft tissue lesions. Accompanied by the in-depth promotion of universal health coverage and wide application of medical imaging technology, the demand for contrast agents in China is high, and contrast agents have a broad application prospect.

In 2022, the scale of China's contrast agents market amounted to over RMB 10 billion.